v3.26.1
Material Agreements (Details) - USD ($)
$ / shares in Units, $ in Thousands
 2 Months Ended 3 Months Ended 65 Months Ended
Apr. 30, 2026
Mar. 03, 2026
Aug. 13, 2025
Mar. 27, 2023
Mar. 02, 2023
Oct. 26, 2022
Sep. 26, 2022
Nov. 03, 2020
Oct. 23, 2020
May 21, 2020
Dec. 31, 2020
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Warrants issued (in shares)   375,000                          
Sale of Stock, Shares Committed, Aggregate Amount   $ 5,000                          
Sale of Stock, Share Commitment, Period following Effective Date (in days)   90 days                          
Revenues                       $ 14,446 $ 8,720    
Assertio Holdings, Inc                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Revenues           $ 6,000                  
Proceeds from collaborators           $ 9,000                  
License and royalty revenue a                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Revenues                       5,395 $ 790    
Minimum                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Warrant exercise price (in dollars per share)   $ 4.00                          
RTW Investments LP | Purchase And Sale Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Exchange for the Purchaser’s payment     $ 75                        
Revenue sharing percentage     9.50%                        
Revenue share payments year ten     $ 187,500                        
Revenue share payments thereafter     $ 225                        
Capitalized Legal Fees                       $ 750   $ 750 $ 700
RTW Investments LP | Purchase And Sale Agreement | Minimum                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Revenue sharing percentage     1.00%                        
RTW Investments LP | Purchase And Sale Agreement | Maximum                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Revenue sharing percentage     7.50%                        
RTW Investments LP | Purchase And Sale Agreement | Senior Notes                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Interest rate (as a percent)     13.50%                        
Commercial exploitation agreement with Indivior                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
License agreement term (in years)                       7 years      
Automatic renewal period of agreement (in years)         1 year             1 year      
License agreement with Sunovion Pharmaceuticals, Inc.                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Aggregate payment                 $ 22,000            
License agreement with Sunovion Pharmaceuticals, Inc. upfront                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Aggregate payment                 5,000            
License agreement with Sunovion Pharmaceuticals, Inc milestones                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Aggregate payment                 $ 17,000            
License agreement with Sunovion Pharmaceuticals, Inc milestones | License and royalty revenue a                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Revenues                   $ 4,000          
MAM Pangolin Royalty , LLC | Maximum                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Proceeds from sale of future revenue               $ 125,000              
MAM Pangolin Royalty , LLC | Monetization Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Proceeds from sale of future revenue               40,000     $ 10,000     $ 50,000  
Additional proceeds from sale of future revenue               10,000              
Proceeds from debt, contingent on additional milestones               $ 75,000              
Zevra And Commave Therapeutics Agreement | License and royalty revenue a                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Revenues                       $ 4,500      
Zevra And Commave Therapeutics Agreement | License and royalty revenue a | Subsequent event                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Revenues $ 500                            
Atnahs Pharma UK Limited | License & Supply Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Proceeds from sale of future revenue             $ 3,500                
Atnahs Pharma UK Limited, Amended Agreement | License & Supply Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Proceeds from sale of future revenue       $ 2,000